Eli Lilly Agrees To Acquire Verve Therapeutics For $10.50/Share In Cash (An Aggregate Of Approximately $1B) Plus One Contingent Value Right Of Up To An Additional $3.00 Per Share, For A Total Potential Consideration Of Up To $13.50 Per Share (An A...

+1.80%

Delist

Eli Lilly and Company

LLY

1027.51

+1.80%

Verve Therapeutics

VERV

11.13

Delist

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease
Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.